EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

Fuxin Xue, Xitong Ren, Chaoying Kong, Jianfeng Wang, Linlin Liu, Junli Hu, Na Shen, Zhaohui Tang

Materials Today Bio · 2024-10 · 28 · 101239

DOI: 10.1016/j.mtbio.2024.101239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Materials Today Bio, 2024-10. Verfasst von Fuxin Xue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jilin Provincial Natural Science Foundation, National Natural Science Foundation of China, Socialist Republic of Vietnam Ministry of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) therapy, particularly PD1/PDL1 inhibition, has demonstrated success in bolstering durable responses in patients. However, the response rate remains below 30 %. In this study, we developed a polymeric bispecific antibody (BsAb) targeting PD1/PDL1 to enhance ICB therapy. Specifically, poly(L-glutamic acid) (PGLU) was conjugated with a double cyclic Fc binding peptide, Fc-III-4C, through condensation reactions between the -COOH group of PGLU and the -NH2 group of Fc-III-4C. This conjugate was then mixed with αPD1 and αPDL1 monoclonal antibodies (mAbs) in an aqueous solution. Mechanistically, the PD1/PDL1 BsAb (BsAbαPD1+αPDL1) acts as a bridge between tumor cells and CD8+ T cells, continuously activating CD8+ T cells to a greater extent. This leads to significantly suppressed tumor growth and prolonged survival in a mouse model of colon cancer compared to treatment with either a single mAb or a mixture of free mAbs. The tumor suppression rate achieved by the BsAbαPD1+αPDL1 was 90.1 %, with a corresponding survival rate of 83.3 % after 48 days. Thus, this study underscores the effectiveness of the BsAbαPD1+αPDL1 as a synchronizing T cell engager and dual ICBs, offering theoretical guidance for clinical ICB therapy.

Schlagwörter

Stichwörter der Autor:innen

Bispecific antibodyCancer immunotherapyFc binding peptidePD1/PDL1 blockageT cell engager

Autor:innen und Institutionen

  • Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China.
  • Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.
  • Key Laboratory of UV-Emitting Materials and Technology, Northeast Normal University, Ministry of Education, Changchun, Jilin, 130024, China.

Förderung

  • Jilin Provincial Natural Science Foundation
  • National Natural Science Foundation of China
  • Socialist Republic of Vietnam Ministry of Science and Technology
  • People's Government of Jilin Province
  • Ministry of Science and Technology of the People's Republic of China
  • Chinese Academy of Sciences Youth Innovation Promotion Association

Zitieren

APA

Xue, F., Ren, X., Kong, C., Wang, J., Liu, L., Hu, J., Shen, N., & Tang, Z. (2024). Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy. Materials Today Bio, 28, 101239. https://doi.org/10.1016/j.mtbio.2024.101239

Vancouver

Xue F, Ren X, Kong C, Wang J, Liu L, Hu J, et al. Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy. Materials Today Bio. 2024;28:101239. doi:10.1016/j.mtbio.2024.101239

BibTeX
@article{Xue2024,
  author = {Xue, Fuxin and Ren, Xitong and Kong, Chaoying and Wang, Jianfeng and Liu, Linlin and Hu, Junli and Shen, Na and Tang, Zhaohui},
  title = {Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy},
  journal = {Materials Today Bio},
  year = {2024},
  volume = {28},
  pages = {101239},
  doi = {10.1016/j.mtbio.2024.101239}
}
Kostenlos starten →